Phase change nanodroplet conjugates for targeted delivery
Phase change nanodroplet conjugates and methods of making and using thereof are provided. The phase change nanodroplet conjugates include a nanodroplet having a gaseous precursor on the interior and an outer shell such as a lipid monolayer, a lipid bilayer, or a polymer layer. The phase change nanodroplet conjugates can have one or more nanoparticles attached to the outer layer, e.g. via a linker. The nanoparticles can include therapeutic, prophylactic, or diagnostic nanoparticles. The phase change nanodroplet conjugates can be used for the targeted delivery of a therapeutic, prophylactic, or diagnostic nanoparticle to a target region in a subject in need thereof. The methods can include applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the liposomes. Methods of making phase change nanodroplet conjugates are also provided.
1. A phase change nanodroplet-nanoparticle conjugate comprising:
a) a nanodroplet comprising a gaseous precursor and an encasing outer shell; and
b) a plurality of nonmetallic nanoparticles covalently linked to the outer shell of the nanodroplet, wherein each nanoparticle comprises an encapsulated therapeutic, prophylactic, or diagnostic agent; and wherein the encapsulation is formed by noncovalent bonds.
2. The conjugate of claim 1 , wherein the outer shell is a lipid monolayer, a lipid bilayer, or a polymer layer.
3. The conjugate of claim 2 , wherein the outer shell comprises a lipid selected from the group consisting of a neutral lipid, a cationic lipid, an anionic lipid, a solid lipid, and a combination thereof.
4. The conjugate of claim 3 , wherein the nonmetallic nanoparticle is selected from the group consisting of a polymeric particle, a lipid particle, a solid lipid particle, a liposome, and combinations thereof.
5. The conjugate of claim 1 , wherein the gaseous precursor comprises one of more molecules with a boiling point of −50° C. to 10° C. at standard pressure.
6. The conjugate of claim 1 , wherein the gaseous precursor comprises a straight chain or branched chain fluorocarbon, hydrofluorocarbon, or fluorohalocarbon having from 2 to 20 carbon atoms, or a combination thereof.
7. The conjugate of claim 1 , wherein the gaseous precursor comprises perfluoropropane, perfluorobutane, or perfluoropentane.
8. A pharmaceutical formulation comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient.
9. A method of targeted delivery of a therapeutic, prophylactic, or diagnostic nanoparticle to a target region in a subject in need thereof, the method comprising:
administering the conjugate of claim 1 .
10. The method of claim 9 , further comprising applying an effective amount of ultrasound radiation to the target region to stimulate vaporization of the gaseous precursor followed by cavitation of the resultant bubble conjugate and release or dispersing of drug or drugs inside the nanoparticles.
11. The method of claim 9 , wherein the target region is a specific cell, tissue, organ, or organ system.
12. The method of claim 9 , wherein the target region is the brain.
13. The method of claim 9 , wherein the subject has cancer and the target region is a tumor.
14. The method of claim 9 where administration is by intravenous injection.
15. The method of claim 9 , wherein the effective amount of ultrasound radiation is effective to release the therapeutic, prophylactic, or diagnostic agent without damaging the target region.
16. A method of making a phase change nanodroplet-nanoparticle conjugate of claim 1 , comprising reacting a first reactive coupling group on an outer shell of the nanodroplet with a second functional group on the nonmetallic nanoparticle to covalently conjugate the nonmetallic nanoparticle to the nanodroplet, wherein the nonmetallic nanoparticle comprises an encapsulated therapeutic, prophylactic, or diagnostic agent.
17. The conjugate of claim 1 , wherein the nonmetallic nanoparticles comprise organic molecules.
18. The conjugate of claim 1 , wherein the nonmetallic nanoparticles comprise noncovalently bonded lipid molecules.
19. The conjugate of claim 18 , wherein the nonmetallic nanoparticles are liposomes encapsulating a drug.